Liver Function Markers and Biological Age
Key Takeaways
- Albumin and alkaline phosphatase appear in widely used clinical biomarker models of biological age, including PhenoAge and common Klemera-Doubal method implementations. [1] [2]
- ALT, AST, GGT, bilirubin, and albumin can reflect liver injury, synthetic function, cholestatic patterns, oxidative stress, or systemic illness rather than ageing alone. [3] [4] [7]
- Some liver markers show age-related or mortality-linked patterns in older cohorts, but these associations are strongly shaped by frailty, adiposity, metabolic disease, alcohol exposure, medication use, and undiagnosed liver disease. [4] [5] [6]
- Liver function markers are best interpreted as one organ-system component of biological-age research, not as standalone measures of whole-body biological age. [1] [3]
Liver-related blood markers are common in ageing research because the liver sits at the intersection of protein synthesis, lipid and glucose metabolism, detoxification, bile handling, inflammation, and systemic disease burden. Biological-age models sometimes use these markers because they capture clinically meaningful physiology from routine blood chemistry panels. [1] [2] [3]
Who This Is Useful For
This page is useful for readers trying to understand why albumin, alkaline phosphatase, ALT, AST, GGT, and bilirubin appear in biological-age calculators, cohort studies, or organ-ageing frameworks. It is especially relevant for readers comparing routine blood-chemistry scores with epigenetic clocks, inflammatory biomarkers, metabolic markers, or kidney-function measures. [1] [2] [3]
What Liver Function Markers Measure
The phrase "liver function test" is imprecise. Albumin is a protein synthesized by the liver and is influenced by inflammation, nutrition, kidney loss, and illness; ALT and AST are aminotransferases often interpreted as hepatocellular injury markers; alkaline phosphatase and GGT are commonly discussed in relation to cholestatic or biliary patterns; and bilirubin reflects heme metabolism, hepatic uptake, conjugation, and excretion. [3] [4] [6]
These markers are therefore not pure measurements of liver ageing. They are mixed physiological signals that can reflect liver structure and function, systemic inflammation, cardiometabolic state, alcohol exposure, medications, muscle injury, frailty, and acute illness. [3] [4] [6] [8]
Common Markers at a Glance
| Marker | What It Often Reflects | Why Ageing Researchers Use It | Main Limitation |
|---|---|---|---|
| Albumin | Hepatic protein synthesis, inflammatory burden, nutritional and disease context | Included in PhenoAge and KDM-style biological-age algorithms | Low values are not specific to liver ageing and can reflect systemic illness |
| Alkaline phosphatase | Biliary tract, liver, bone, and other tissue sources | Included in PhenoAge and many blood-chemistry age models | Can reflect bone turnover or cholestatic disease rather than ageing rate |
| ALT | Hepatocellular injury and, in older cohorts, possible low-muscle or frailty-related patterns | Studied because ALT tends to change with age and predicts outcomes in some cohorts | Both high and unusually low values can be difficult to interpret without context |
| AST | Liver, muscle, cardiac, red-cell, and other tissue injury signals | Sometimes used with ALT or in broader liver-enzyme panels | Less liver-specific than ALT and sensitive to muscle-related confounding |
| GGT | Biliary enzyme activity, alcohol and metabolic exposures, oxidative-stress-associated patterns | Associated with mortality and cardiometabolic outcomes in several cohorts | Highly non-specific and exposure-sensitive |
| Bilirubin | Heme turnover, hepatic processing, biliary excretion, and inherited variation | Sometimes included in liver-ageing frameworks or enzyme-outcome studies | Interpretation depends on fraction, genetics, hemolysis, and cholestasis context |
Why They Appear in Biological-Age Models
Clinical biological-age models use routine blood chemistry because these measurements are inexpensive, repeatable, and linked to morbidity and mortality in large cohorts. In the PhenoAge framework, albumin and alkaline phosphatase are part of the clinical phenotypic-age equation, alongside kidney, inflammatory, glucose, immune, and hematologic markers. [1]
Klemera-Doubal method implementations also often include albumin and alkaline phosphatase when estimating biological age from clinical chemistry. The BioAge toolkit describes published and modified KDM, PhenoAge, and homeostatic-dysregulation versions that use these markers as part of broader multi-system panels. [2] [11]
Their inclusion does not mean the liver alone determines biological age. It means that liver-associated chemistry contributes independent information to a multi-marker mortality or physiological-dysregulation model. [1] [2]
How Liver Ageing Differs From Liver Disease
Reviews of liver physiology describe age-related changes in liver volume, hepatic blood flow, sinusoidal structure, regenerative capacity, and drug-handling physiology, while also emphasizing that many baseline liver functions can remain relatively preserved in healthy older adults. [9] [10]
This distinction matters because routine liver markers are often more sensitive to disease and exposure than to intrinsic ageing. A high ALT or GGT value may reflect metabolic dysfunction-associated steatotic liver disease, alcohol exposure, medication effects, viral hepatitis, or cholestasis; it should not be treated as a direct clock of liver ageing. [3] [6] [7]
ALT, Frailty, and Older Age
ALT is usually introduced clinically as a liver-injury marker, but ageing cohorts show a more nuanced pattern. In older community-dwelling men, lower ALT was associated with older age, frailty, disability, and reduced survival, suggesting that very low ALT may sometimes track reduced physiological reserve rather than healthier liver status. [4]
The Rancho Bernardo Study similarly reported that ALT decreased with age in a community cohort, including values within conventional reference ranges. This pattern illustrates why ageing research often cares about distributions and outcomes, not only whether a marker is above a clinical abnormality threshold. [5]
GGT, ALP, and Mortality Signals
GGT and alkaline phosphatase have been associated with mortality in older population cohorts, including analyses from the Rotterdam Study and the Rancho Bernardo Study. These findings support their use as risk-associated biomarkers, but the observed associations do not make them specific ageing mechanisms. [6] [7]
GGT is also frequently discussed as a marker linked to oxidative stress and cardiometabolic risk. In older adults, studies combining GGT with oxidative-stress-related markers report associations with adverse outcomes, reinforcing its role as a broad risk signal rather than a liver-only measurement. [8]
Albumin as a Systemic Marker
Albumin has a liver-synthesis component, but in older adults it is also shaped by inflammation, nutritional state, kidney losses, acute illness, and chronic disease burden. Older cohort studies have linked low albumin with disability and mortality, which helps explain why albumin appears in biological-age equations. [1] [12]
For biological-age interpretation, albumin is better understood as a systemic reserve and illness-burden marker with hepatic input, rather than as a narrow measure of liver age. [1] [12]
Why Interpretation Is Hard
Liver markers are sensitive to confounding. Alcohol exposure, adiposity, metabolic syndrome, viral hepatitis, medications, muscle injury, hemolysis, bone turnover, acute infection, and laboratory methods can all shift values in ways that are not reducible to biological age. [3] [4] [6] [8]
A second difficulty is that clinical reference ranges and ageing-risk gradients answer different questions. A marker can sit inside a routine reference interval while still contributing to risk prediction in a population model, and a marker outside a reference interval may reflect a specific disease process rather than accelerated ageing. [1] [5] [6]
Evidence Quality and Interpretation
Confidence is strong that albumin and alkaline phosphatase are established components of several clinical biomarker-based biological-age models, including PhenoAge and common KDM implementations. [1] [2] [11]
Confidence is moderate that liver-enzyme patterns add useful risk information in older cohorts, because ALT, ALP, AST, and GGT have been associated with age, frailty, disability, and mortality in multiple observational settings. The direction and meaning of those associations vary by marker and cohort. [4] [5] [6] [7]
Confidence is weaker for interpreting any individual liver marker as a direct biological-age readout, because the same value can arise from liver disease, systemic illness, body composition, medication exposure, alcohol use, muscle injury, or laboratory context. [3] [6] [8]
What This Does Not Mean
- It does not mean a single liver marker can define a person's biological age. [1] [2]
- It does not mean a normal liver panel proves slow ageing or absence of liver disease. [3] [10]
- It does not mean high ALT, AST, ALP, GGT, or bilirubin should be interpreted primarily as ageing rather than possible disease or exposure context. [3] [6]
- It does not mean low ALT or low albumin always has the same explanation across populations, because frailty, inflammation, nutrition, and disease burden can differ across cohorts. [4] [12]
Practical Interpretation Examples
- If albumin is low in an older cohort: that may contribute to higher biological-age or mortality-risk estimates, but it does not identify liver ageing as the sole cause. [1] [12]
- If alkaline phosphatase raises a PhenoAge score: the model is using ALP as a risk-associated clinical marker, not as a direct measurement of liver age. [1]
- If ALT is unusually low in older adults: cohort studies suggest possible links with frailty and reduced survival, but interpretation still depends on muscle mass, illness, and clinical context. [4] [5]
- If GGT is elevated: the signal may overlap with liver disease, oxidative stress, alcohol exposure, or cardiometabolic risk rather than ageing alone. [7] [8]
Related Reading
Summary
Liver function markers matter in biological-age research because they capture clinically relevant physiology and contribute to multi-system risk models. Their strongest role is as part of broader blood-chemistry panels that integrate liver-associated, inflammatory, metabolic, kidney, immune, and hematologic information. Interpreted alone, they are too non-specific to define biological age or liver ageing without disease, exposure, and measurement context. [1] [2] [3]
References
- Levine, M. E., Lu, A. T., Quach, A., Chen, B. H., Assimes, T. L., Bandinelli, S., et al. (2018). An epigenetic biomarker of aging for lifespan and healthspan. Aging. https://pmc.ncbi.nlm.nih.gov/articles/PMC5940111/
- Kwon, D., & Belsky, D. W. (2021). A toolkit for quantification of biological age from blood chemistry and organ function test data: BioAge. GeroScience. https://pmc.ncbi.nlm.nih.gov/articles/PMC8602613/
- Aging Biomarker Consortium, Jiang, M., Zheng, Z., Wang, X., Chen, Y., Qu, J., et al. (2024). A biomarker framework for liver aging: the Aging Biomarker Consortium consensus statement. Life Medicine. https://pmc.ncbi.nlm.nih.gov/articles/PMC11749002/
- Le Couteur, D. G., Blyth, F. M., Creasey, H. M., Handelsman, D. J., Naganathan, V., Sambrook, P. N., et al. (2010). The association of alanine transaminase with aging, frailty, and mortality. Journal of Gerontology: Medical Sciences. https://pmc.ncbi.nlm.nih.gov/articles/PMC4085878/
- Dong, M. H., Bettencourt, R., Barrett-Connor, E., Loomba, R. (2010). Alanine aminotransferase decreases with age: the Rancho Bernardo Study. PLoS ONE. https://pmc.ncbi.nlm.nih.gov/articles/PMC2999530/
- Koehler, E. M., Sanna, D., Hansen, B. E., van Rooij, F. J. A., Heeringa, J., Hofman, A., et al. (2014). Serum liver enzymes are associated with all-cause mortality in an elderly population. Liver International. https://pubmed.ncbi.nlm.nih.gov/24219360/
- Ruhl, C. E., & Everhart, J. E. (2013). Serum gamma-glutamyltransferase predicts all-cause, cardiovascular and liver mortality in older adults. Journal of Clinical Epidemiology. https://pubmed.ncbi.nlm.nih.gov/23997501/
- Spoto, B., Mattace-Raso, F., Sijbrands, E. J., D'Arrigo, G., Tripepi, G., Volpato, S., et al. (2017). Oxidized LDL, gamma-glutamyltransferase and adverse outcomes in older adults. Journal of the American Geriatrics Society. https://pubmed.ncbi.nlm.nih.gov/28422277/
- Wynne, H. A., Cope, L. H., Mutch, E., Rawlins, M. D., Woodhouse, K. W., & James, O. F. W. (1989). The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology. https://pubmed.ncbi.nlm.nih.gov/2643548/
- Kim, I. H., Kisseleva, T., & Brenner, D. A. (2013). Liver physiology and liver diseases in the elderly. World Journal of Gastroenterology. https://pmc.ncbi.nlm.nih.gov/articles/PMC3870491/
- Klemera, P., & Doubal, S. (2006). A new approach to the concept and computation of biological age. Mechanisms of Ageing and Development. https://pubmed.ncbi.nlm.nih.gov/16318865/
- Corti, M. C., Guralnik, J. M., Salive, M. E., & Sorkin, J. D. (1994). Serum albumin level and physical disability as predictors of mortality in older persons. JAMA. https://pubmed.ncbi.nlm.nih.gov/8089886/
This content is provided for educational purposes only and does not constitute medical advice.